Pulmonx Corporation (LUNG) Dividend History

Company News

• 5 Medical Info Systems Stock to Buy for a Stable Portfolio

  We have narrowed our search to five medical info systems stocks. These are: HIMS, ENOV, LUNG, PHR, LAB.

  Zacks Investment Research

  Featured Companies: ENOV HIMS LAB PHR
• Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

  REDWOOD CITY, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced that the Compensation Committee of the Board of Directors of Pulmonx (the “Compensation Committee”) granted inducement awards consisting of a non-statutory stock option to purchase 241,409 shares of common stock and a time-based restricted stock unit award for 125,870 shares of common stock on May 6, 2024 to Mehul Joshi in connection with his appointment as the Chief Financial Officer of Pulmonx in April 2024.

  GlobeNewswire Inc.
• Navigating 6 Analyst Ratings For Pulmonx

  Analysts' ratings for Pulmonx (NASDAQ:LUNG) over the last quarter vary from bullish to bearish, as provided by 6 analysts. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 3 1 0 0 Last 30D 0 1 0 0 0 1M Ago 0 0 0 0 0 2M Ago 2 2 1 0 0 3M Ago 0 0 0 0 0 Analysts have recently evaluated Pulmonx and provided 12-month price targets. The average target is $16.33, accompanied by a high estimate of $17.00 and a low estimate of $14.00. This upward trend is apparent, with the current average reflecting a 6.52% increase from the previous average price target of $15.33. Breaking Down Analyst Ratings: A Detailed Examination The standing of Pulmonx among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Jason Bednar Piper Sandler Maintains Overweight $17.00 $17.00 Joanne Wuensch Citigroup Raises Buy $17.00 $16.00 Larry Biegelsen Wells Fargo Lowers Equal-Weight $14.00 $16.00 Rick Wise Stifel Raises Buy $17.00 $15.00 Jason Bednar Piper Sandler Raises Overweight $17.00 $13.00 Larry Biegelsen Wells Fargo Raises Overweight $16.00 $15.00 Key Insights: Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to ...Full story available on Benzinga.com

  Benzinga
• Why Shares of Pulmonx Rose This Week

  Thanks to sales of its Zephyr valve, the company's revenue is growing.

  The Motley Fool